GlobeNewswire
Fortress Biotech Announces Oral and Poster Data Presentations at the 62nd American Society of Hematology (ASH) Annual Meeting
Clinical data on CAEL-101 for AL amyloidosis and MB-106 CD20-targeted CAR T cell therapy to be presentedNEW YORK, Nov. 04, 2020 (GLOBE NEWSWIRE) — Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative revenue-generating company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and…
Source link
